Hengrui Pharma(SH:600276) GLP1减重宝典·2025-08-26 09:15Core Viewpoint - The article highlights the positive results of the phase III clinical trial for HRS9531, a GLP-1/GIP dual receptor agonist developed by Heng Rui Medicine, indicating its effectiveness in treating obesity or overweight individuals in China [2][4]. Group 1: Clinical Trial Results - The trial included 567 participants with an average baseline weight of 93 kg, showing that after 48 weeks of treatment, the average weight loss reached up to 17.7% compared to a 16.3% reduction in the placebo group [4]. - The proportion of participants achieving a weight loss of ≥5% was 88.0%, with 44.4% of those in the high-dose group losing ≥20% of their body weight [4]. - Supplementary analysis indicated an average weight loss of up to 19.2% in the treatment group, adjusted for placebo [4]. Group 2: Safety and Regulatory Plans - HRS9531 demonstrated good safety and tolerability, with most adverse events being mild to moderate, primarily gastrointestinal in nature [6]. - Heng Rui Medicine plans to submit a new drug application for HRS9531 for long-term weight management in China soon [7].